PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
No SEC Form 4 filings for $PACB in the last 30 days.
Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2026 revenue of $39.01 million, down 1.9% year on year and below analyst expectations. Non-GAAP adjusted EPS was -$0.14, missing consensus. Analysts expect revenue to rise 14.2% over the next 12 months and full-year EPS to improve from -$0.50 to -$0.48. Shares fell 1.1% to $1.28 after results.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exhibit991-earningsrelease.htm EX-99.1 Document Exhibit 99.1 PacBio Announces Second Quarter 2026 Financial Results MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent
PacBio (NASDAQ: PACB) said it will add SPRQ-Nx chemistry and a software update for its Vega sequencing system. The chemistry uses Revio core chemistry to raise HiFi output from 60 Gb to 90 Gb per run and cut the U.S. list price from $1,100 to $995. The update adds 2- and 4-hour runs, new methylation callers, and 21 CFR Part 11 compliance controls. Shipping and download are planned by month-end.
Over the past 7 days, alphai's AI scored 4 news stories mentioning PACB (PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent PACB coverage spans financial news, earnings and technology.
The miss on both revenue and adjusted EPS increases near-term downside risk to expectations and supports a cautious stance until next-quarter execution improves.
The filing provides fresh quarterly datapoints and a new full-year revenue range, which can reset near-term expectations for instrument pull-through and consumables growth.
The release is a product-and-pricing upgrade for PacBio’s Vega platform, potentially improving unit economics and expanding in-house HiFi adoption.
Earnings are the near-term catalyst, with the key debate centered on whether revenue can re-accelerate after recent misses.
Board turnover can affect governance optics and committee leadership, but the filing provides no operational disagreement or replacement details.
alphai scores every news story that mentions PACB with an AI model for sentiment and relevance, and aggregates insider trades from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2026 revenue of $39.01 million, down 1.9% year on year and below analyst expectations. Non-GAAP adjusted EPS was -$0.14, missing consensus. Analysts expect revenue to rise 14.2% over the next 12 months and full-year EPS to improve from -$0.50 to -$0.48. Shares fell 1.1% to $1.28 after results.
5 min readPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exhibit991-earningsrelease.htm EX-99.1 Document Exhibit 99.1 PacBio Announces Second Quarter 2026 Financial Results MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent
6 min readPacBio (NASDAQ: PACB) said it will add SPRQ-Nx chemistry and a software update for its Vega sequencing system. The chemistry uses Revio core chemistry to raise HiFi output from 60 Gb to 90 Gb per run and cut the U.S. list price from $1,100 to $995. The update adds 2- and 4-hour runs, new methylation callers, and 21 CFR Part 11 compliance controls. Shipping and download are planned by month-end.
4 min readPacific Biosciences of California (NASDAQ: PACB) will report earnings Wednesday afternoon. Last quarter it reported revenue of $37.18 million, flat year over year, missing analysts’ revenue expectations, while EPS beat. This quarter, analysts expect revenue to be flat. The article cites an average analyst price target of $2.46 versus $1.43.
3 min readPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pacb-20260708 0001299130 false 0001299130 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) Ju
2 min readThe article compares Q1 results across life-sciences tools stocks. West Pharmaceutical Services posted the biggest analyst estimate beat; its shares were up 18% to $323.85. Azenta reported $144.8M revenue (+1% YoY), missing expectations by 2.5%, and shares fell 5.8% to $23.19. Bruker revenue was $823.4M (+2.7%), beating by 3.4%, shares up 56% to $59.30. Illumina revenue was $1.09B (+4.8%), beating by 1.8%, shares up 29.1% to $163.68.
6 min readPacific Biosciences of California, Inc. (PACB) reported Q1 2026 revenue of $37.2 million, flat year-over-year, with higher consumable sales offsetting declines in instrument and service revenue. The company significantly narrowed its net loss to $8.3 million, down from $426.1 million in Q1 2025, largely due to a $45.8 million gain on an asset sale to Illumina and reduced operating expenses. PACB expects sequential revenue growth in Q2 2026 and further improvements in the second half of the year driven by clinical adoption, SPRQ-Nx consumable growth, and its Basecamp Research program.
3 min readPacific Biosciences of California has introduced a new heat-then-extract workflow for adeno-associated virus (AAV) genome analysis. This innovative method aims to reduce partial snapback genomes and increase the proportion of full-length genomes, offering significant improvements for researchers in gene therapy and genome sequencing. The company will present these findings at the ASGCT2026 conference, continuing its focus on advancing genome analysis technologies.
3 min readPacific Biosciences of California (PACB) shares closed down 6.96% at $1.47, underperforming the broader S&P 500. The company is set to report earnings on May 7, 2026, with analysts anticipating an EPS of -$0.17 and revenue of $41 million. Despite the recent dip, the stock has gained 19.7% over the past month, and currently holds a Zacks Rank #3 (Hold).
3 min readPacific Biosciences of California has updated its SMRT Cell Sequencing 101 guide to reflect the latest advancements in its PacBio HiFi sequencing, including the integration of SPRQ-Nx chemistry. This revision provides an up-to-date view of sequencing capabilities in a single run. The company continues to focus on enhancing high-accuracy genomic analysis tools, previously launching the HiFi sequencing and Vega system for oncology and introducing new solutions for whole genome sequencing and cancer variant detection.
3 min read
